Conditions: Psoriasis
Keywords: Xeljanz tofacitinib chronic Pruritus Itch DLQI severe moderate treatment safety efficacy CP-690,550 Plaque Psoriasis Psoriasis Vulgaris Jax-inhibitor Oral Treatment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 901
Healthy volunteers: no

Brief summary:
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: CP-690,550 intervention 2: CP-690,550 intervention 3: Placebo/CP-690,550 intervention 4: Placebo/CP-690,550
Intervention descriptions: intervention 1: 10 mg oral BID, Continuous treatment for 52 Weeks intervention 2: 5 mg oral BID, Continuous treatment for 52 Weeks intervention 3: 0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo) intervention 4: 0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

Protocol document: